In December 2023, we informed about concluding an advisory agreement with CET Advisors LTD in the commercialization process of projects conducted by NanoSanguis S.A. (hereinafter also referred to as the “Company”). On Friday, June 21, 2024, CET concluded an agreement with the Company to acquire 100,000 shares of Nanosanguis S.A. This is also the fulfillment of the provisions of the agreement concluded in December last year. Thus, CET becomes a shareholder of NanoSanguis S.A.
At the same time, based on the agreement concluded with CET in December 2023, he is entitled to apply to NanoSanguis S.A. with a request to convert the purchased 100,000 shares of the Company into shares of Nanogroup S.A. in the ratio of 613 shares of Nanogroup S.A. for each 100 shares of NanoSanguis S.A. held by CET. Management Board of NanoSanguis S.A. has undertaken to perform all activities enabling such conversion. To carry it out, the consent of the governing bodies of NanoGroup S.A. is required, including a resolution of the general meeting. The shares of NanoGroup S.A. obtained by CET as a result of the conversion. will be subject to a 12-month sales ban from the date of their acquisition by CET.
CET is part of the Clairfield International SA group based in Geneva and as a group provides advisory services in the field of sale and purchase of enterprises as well as mergers and acquisitions. The group has extensive experience in transactions with companies from the medical technology and biotechnology industries, with successes in the global commercialization of products from the Polish biotechnology market.
We are glad that such a renowned transaction advisor believes in the project and the possibility of achieving great success by NanoSanguis S.A.